PETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D. has joined the Company’s Medical Advisory Board. RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies. Dr. Dritschilo is a renowned educator, inventor, translational scien
Tapering is best reserved for those in complete remission with stable disease for at least 6 months, although many individual patient characteristics must be taken into account, experts say.